A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
Stéphanie Gaillard(Sidney Kimmel Cancer Center), Nilofer S. Azad(Johns Hopkins Hospital), Michelle A. Rudek(Dana-Farber Cancer Institute), Jennifer N. Durham(Sidney Kimmel Comprehensive Cancer Center), Anup Sharma(Johns Hopkins University), Marianna Zahurak(Bloomberg (United States)), Susan Sartorius‐Mergenthaler(Johns Hopkins University), Nita Ahuja(Johns Hopkins University), Kim A. Reiss(University of Pennsylvania), Melinda Downs(Johns Hopkins University), Nicole M. Anders(Johns Hopkins University)
Cited by 56
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k